



31 May 2022

Results of Annual General Meeting

Creso Pharma Limited (ASX:CPH) ('Creso Pharma' or 'the Company') held its 2022 Annual General Meeting of Members by virtual meeting facility today.

All resolutions were determined by a poll.

The outcome of each resolution put to shareholders at the Annual General Meeting is set out in the Annexure which accompanies this release.

Ends

Authority and Contact Details

This announcement has been authorised for release by Winton Willesee, Joint Company Secretary.

For further information, please contact:

Investor Enquiries

Creso Pharma Limited

E: info@cresopharma.com

P: +61 (0) 497 571 532

About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com

Disclosure of Proxy Votes

Creso Pharma Limited

Annual General Meeting

Tuesday, 31 May 2022



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Adoption of Remuneration Report	P	161,406,491	130,999,773 81.16%	24,420,852 15.13%	14,503,869	5,985,866 3.71%	136,985,639 84.87%	24,420,852 15.13%	14,503,869
2 Re-Election of Director – Adam Blumenthal	P	314,296,683	283,992,031 90.36%	25,191,374 8.02%	771,128	5,113,278 1.63%	289,105,309 91.98%	25,191,374 8.02%	771,128
3 Election of Director – William Lay	P	314,379,028	306,434,096 97.47%	2,186,911 0.70%	688,783	5,758,021 1.83%	312,192,117 99.30%	2,186,911 0.70%	688,783
4 Election of Director – Micheline Mackay	P	312,271,149	285,246,743 91.35%	21,266,385 6.81%	2,796,662	5,758,021 1.84%	291,004,764 93.19%	21,266,385 6.81%	2,796,662
5 Election of Director – Bruce Linton	P	312,214,715	304,914,680 97.66%	2,174,307 0.70%	2,853,096	5,125,728 1.64%	310,040,408 99.30%	2,174,307 0.70%	2,853,096
6 Approval of 7.1A Mandate	P	313,609,821	301,839,734 96.25%	5,568,105 1.78%	1,457,990	6,201,982 1.98%	308,041,716 98.22%	5,568,105 1.78%	1,457,990
7 Amendment to Constitution	P	313,705,563	285,141,032 90.89%	22,614,414 7.21%	1,362,248	5,950,117 1.90%	291,091,149 92.79%	22,614,414 7.21%	1,362,248

